Jefferies Raises PT From $21.00 To $25.00 On Amarin (AMRN)

In a recent report, Jefferies has raised the price target on Amarin AMRN from $21.00 to $25.00 after a AMR101 patent discussion with the FDA. In the report, Jefferies said, "We believe a longer-than-expected Hatch-Waxman patent extension of 5 years (vs. company guidance of 2 years) could extend AMR101 U.S. market exclusivity from 2022 to 2025." Amarin closed Friday at $17.00.